Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
July 22, 2019
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Jatin Shah, Saad Usmani, Edward A Stadtmauer, et al.
The Oncologist
|
November 10, 2017
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies
Rami Komrokji, Arlene S Swern, David Grinblatt, et al.
British Journal of Haematology
|
February 26, 2013
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
David J Kuter, James B Bussel, Adrian Newland, et al.
British Journal of Haematology
|
August 31, 2019
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy
Fevzi F Yalniz, Jesus G Berdeja, Michael B Maris, et al.
Journal of Hematology & Oncology
|
May 2, 2012
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Azra Raza, Naomi Galili, Deborah Mulford, et al.
Blood Cancer Journal
|
September 19, 2023
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2009
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes
Roger M Lyons, Thomas M Cosgriff, Sanjiv S Modi, et al.
The Lancet. Haematology
|
August 2, 2016
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
Gary E Raskob, Nick van Es, Annelise Segers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2009
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia
Hagop Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Research and Practice in Thrombosis and Haemostasis
|
February 4, 2021
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
Adam Cuker, Jenny M Despotovic, Rachael F Grace, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Clinical Lymphoma, Myeloma & Leukemia
|
July 22, 2019
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Jatin Shah, Saad Usmani, Edward A Stadtmauer, et al.
The Oncologist
|
November 10, 2017
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies
Rami Komrokji, Arlene S Swern, David Grinblatt, et al.
British Journal of Haematology
|
February 26, 2013
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
David J Kuter, James B Bussel, Adrian Newland, et al.
British Journal of Haematology
|
August 31, 2019
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy
Fevzi F Yalniz, Jesus G Berdeja, Michael B Maris, et al.
Journal of Hematology & Oncology
|
May 2, 2012
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Azra Raza, Naomi Galili, Deborah Mulford, et al.
Blood Cancer Journal
|
September 19, 2023
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2009
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes
Roger M Lyons, Thomas M Cosgriff, Sanjiv S Modi, et al.
The Lancet. Haematology
|
August 2, 2016
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
Gary E Raskob, Nick van Es, Annelise Segers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2009
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia
Hagop Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Research and Practice in Thrombosis and Haemostasis
|
February 4, 2021
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
Adam Cuker, Jenny M Despotovic, Rachael F Grace, et al.
Page
of 5